Ranbaxy sale to Sun Pharmaceuticals appears on track

The U.S. Federal Trade Commission said the $4 billion deal for Japan's Daiichi Sankyo to sell its troubled Ranbaxy Laboratories unit to Sun Pharmaceutical looks to be OK as long as Ranbaxy divests its generic minocycline antibacterial to Torrent Pharmaceuticals. Daiichi has been looking to rid itself of Ranbaxy following a number of plant issues in India that have resulted in FDA investigations and warnings. The FTC issued a consent order for comments that runs through March 3, then the agency will decide whether to grant the final order for the merger. If approved, Sun has said the deal could close within weeks. Story

Suggested Articles

McCallum was hit with a warning letter from the FDA for testing issues with its products and failing to keep appropriate records.

The FDA made public a voluntary recall of sterile injectables made by Coastal Meds of Mississippi, after visible particles were found in some vials.

It’s been a strange road for BMS' Opdivo-Yervoy combo in first-line kidney cancer, but the New Jersey drugmaker finally has a go-ahead.